RHEOPOLYGLUKIN-40 — Medpolymer

Marketing Authorisation No. P N002048/01

Composition:

Dextran 40 000 – 100.0 g,

Sodium chloride – 9.0 g,

Water for injections – up to 1.0 L.

Theoretical osmolarity – 310 mOsm/L

Therapeutic class: plasma volume expander

100 ml

200 ml

250 ml

400 ml

500 ml

Pharmacological effect. Rheopolyglukin-40 is a preparation of low molecular weight dextran. It reduces the aggregation of the formed elements and promotes the movement of fluid from the tissues into the bloodstream. Consequently, the drug increases the suspension-stability of blood, reduces its viscosity, faciliates blood flow recovery in small capillaries, has a detoxifying effect, and prevents and reduces aggregation of blood formed elements.

Dextran is excreted renally (up to 70% in the first 24 hours).

Indications. Rheopolyglucin-40 is intended for treatment of capillary blood flow disorders, for prevention and treatment of traumatic, surgical and burn shock; arterial and venous circulation disorders, for treatment and prevention of thrombosis, thrombophlebitis, endoarteritis; During heart surgeries performed using a heart-lung machine (to add to perfusion fluid), in vascular and plastic surgery to improve local circulation; for detoxification in burns, peritonitis, pancreatitis, etc. Rheopolyglucin - 40 is administered in the retina and optic nerve diseases, in the cornea and uvea inflammatory processes.

Shelf life: 3 years.